BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20306194)

  • 1. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
    Wittenburg LA; Bisson L; Rose BJ; Korch C; Thamm DH
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):83-92. PubMed ID: 20306194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
    Saha SK; Yin Y; Kim K; Yang GM; Dayem AA; Choi HY; Cho SG
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28498322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
    Rathore K; Cekanova M
    Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
    Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
    Igarashi K; Yamamoto N; Hayashi K; Takeuchi A; Kimura H; Miwa S; Hoffman RM; Tsuchiya H
    Anticancer Res; 2016 Sep; 36(9):4477-82. PubMed ID: 27630284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.
    Wittenburg LA; Gustafson DL; Thamm DH
    Clin Cancer Res; 2010 Oct; 16(19):4832-42. PubMed ID: 20705615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
    Wittenburg LA; Ptitsyn AA; Thamm DH
    J Cell Biochem; 2012 Mar; 113(3):773-83. PubMed ID: 21976144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.
    Wang CK; Yu XD; Li Q; Xie G; Teng Y
    Asian Pac J Cancer Prev; 2013; 14(8):4651-4. PubMed ID: 24083719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
    Machado MC; Bellodi-Privato M; Kubrusly MS; Molan NA; Tharcisio T; de Oliveira ER; D'Albuquerque LA
    J Exp Ther Oncol; 2011; 9(2):85-92. PubMed ID: 21699015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
    Liu P; Tian X; Shi GR; Jiang FY; Liu BQ; Zhang ZH; Zhao L; Yan LN; Liang ZQ; Hao CL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):458-62. PubMed ID: 22213865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines.
    Igarashi K; Kawaguchi K; Kiyuna T; Murakami T; Miwa S; Nelson SD; Dry SM; Li Y; Singh AS; Kimura H; Hayashi K; Yamamoto N; Tsuchiya H; Eilber FC; Hoffman RM
    Anticancer Res; 2017 Aug; 37(8):4081-4084. PubMed ID: 28739691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
    Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
    Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
    Wang Z; Liu Z; Wu S
    Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
    Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
    J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
    Jones J; Juengel E; Mickuckyte A; Hudak L; Wedel S; Jonas D; Blaheta RA
    J Cell Mol Med; 2009 Aug; 13(8B):2376-2385. PubMed ID: 18657224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.